🎯Lower GI- Proffered paper (Day-3) #ESMO24 ESMO - Eur. Oncology 📝IMHOTEP 💉Neoadjuvant and adjuvant pembro in dMMR colorectal cancer ✅pCR ⬆️ OncoAlert IntraMed Oncología ESMO - Eur. Oncology

#ESMO24 🎯Super compelling data from #CM9ER evaluating #cabozantinib #nivolumab suggesting a potential predictive role of glycosylation of certain complement mediating peptides IntraMed Oncología ESMO - Eur. Oncology OncoAlert

⭕️Dr. Sheng presents the results of ETER100 a randomized ph3 study comparing anltonib + bemmelstobart in aRCC 📝Improved PFS and ORR in the experimental arm!@myESMO OncoAlert IntraMed Oncología

45 Posts not to miss from ESMO - ESMO - Eur. Oncology Day 1 OncoDaily oncodaily.com/societies/1428… IntraMed Oncología Martín Angel Rodrigo Sanchez Roger

📝Comprehensive overview of non-clear cell RCC subtypes by Pedro C Barata, MD MSc FACP including important work on tRCC Ziad Bakouny, MD, MSc Srinivas Viswanathan ! #ESMO2024 IntraMed Oncología OncoAlert

Ipi-Nivo in metastatic melanoma continue demostrated benefit 10 years latter! 💪🏻 IntraMed Oncología

🎯UNITE analysis of EV-associated peripheral neuropathy (n=485) 📌36% of pts (grade 3+: 4%). Median time to PN: 2.5 mo IntraMed Oncología OncoReporte ESMO - Eur. Oncology OncoAlert

⭕️Terrific talk by Arun Azad delivering the results of randomized ph2 UpFrontPSMA using Lu-177-PSMA-617 & docetaxel in pts w/ mHSPC #prostatecancer 👉🏻 🎯Trial met its primary endpoint of undetectable PSA at 48 weeks w/ ORR ESMO - Eur. Oncology IntraMed Oncología OncoAlert

⭕️Outstanding discussion by Camillo Porta on microbiota transplantation in patients with cancer ‼️Significant challenges in determining the source of microbiota ESMO - Eur. Oncology IntraMed Oncología UroToday.com OncoAlert

GI- Mini oral (Day-4) #ESMO24 🎯Response to neoadjuvant FLOT to decide adjuvant FLOT? ✅Only partial responders benefit from adjuvant treatment ❗️ ❗️Prospective clinical trials is needed OncoAlert IntraMed Oncología ESMO - Eur. Oncology

⭕️Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR 🎯nej.md/4gh1b9D ESMO - Eur. Oncology OncoAlert IntraMed Oncología

⭕️NIAGARA: Fase III Quimio vs Quimio+Durvalumab neoadjuvante & cistetctomía en Ca urotelial músculo invasor en IntraMed Oncología ESMO - Eur. Oncology OncoAlert ⬇️ 25% en el riesgo de muerte ⬆️ 10% tasas de pCR 🎯Primera IO neo/adyuvante con beneficio en OS ‼️Nuevo estándar de tratamiento‼️

📝GI- Mini oral 💉nal-IRI plus S-1 vs. 5FU in 2L of advanced pancreatic cancer ❌No PFS benefit ❌OS tend to be better with 5FU ❌More toxicity ESMO - Eur. Oncology IntraMed Oncología OncoAlert

Interesting presentations on sequencing in advanced melanoma in ESMO - Eur. Oncology We need to continue researching and finding new strategies for patients resistant to current treatments 🧬📑 IntraMed Oncología

Outstanding lecture by Shilpa Gupta putting in context all the proffed papers in #blcsm at #ESMO24 IntraMed Oncología Asociación Argentina de Oncología Clínica (AAOC) Unmet need ➡️ more Bladder preservation strategy

The new kid on the Block! Onther Doblete in mCSPC #ARANOTE #ESMO24 Asociación Argentina de Oncología Clínica (AAOC) IntraMed Oncología

⭕️Neuroendocrine markers in IHC and genomic alterations are associated with the survival in 🎯PEACE-1 ancillary study IntraMed Oncología ESMO - Eur. Oncology OncoAlert

Congratulations to stampede group for looking for ADT altwrnatives to improve #QoL in #pcsm #ESMO24 IntraMed Oncología

Interrumpir la HT en cáncer de mama de alto riesgo por deseos de maternidad 🤰, es una posibilidad segura. Sin dudas unas gran novedad para muchas pacientes jovenes con cáncer de mama 👏🏻 ESMO - Eur. Oncology

Felicitaciones a los autores por este gran trabajo cooperativo #EU & #LATAM Federico Esteso Andres Cervantes Juan OConnor Cinthia 🇪🇺 🇦🇷 🇵🇾 🇲🇽 🇨🇱 ESMO - Eur. Oncology IntraMed Oncología